A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma.

Trial Profile

A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Erlotinib (Primary) ; Etoposide
  • Indications Ependymoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PETEY
  • Sponsors OSI Pharmaceuticals
  • Most Recent Events

    • 04 Apr 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov. (Parent trial: NCT01032070).
    • 04 Apr 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov. (Parent trial: NCT01032070).
    • 12 Dec 2012 Planned end date changed from 1 Jun 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov. (Parent trial: NCT01032070)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top